Onur KARSLI, Ahmed Ömer HALAT, Murat ÜSTÜNER, Bekir VOYVODA, Ömür MEMİK

İntravezikal Prostatik Protrüzyonun Prostat Histopatolojisini Öngörme Değeri

GİRİŞ ve AMAÇ: Benign prostat hiperplazisinde mesane çıkış obstrüksiyonunun önemli belirteçlerinden biri de intravezikal prostatik protrüzyondur (İPP). Biz bu çalışmamızda prostat spesifik antijen (PSA) yüksekliği nedeniyle transrektal ultrason (TRUSG) biyopsi yapılan hastalarda İPP ile benign patolojiler arasındaki korelasyonu göstermeyi amaçladık. YÖNTEM ve GEREÇLER: Ocak 2018 Ocak 2020 arasında kliniğimizde PSA yüksekliği nedeniyle TRUSG eşliğinde biyopsi yapılan 90 hasta çalışmaya dahil edildi. Transabdominal USG ile İPP ölçümü yapılan hastaların yaş, PSA, IPP ölçüsü ve derecesi, patoloji sonucu kaydedildi. Hastalar protrüzyon derecesine göre 3 gruba ayrıldı. Üç grubun PSA değerleri, patoloji sonuçları, prostat volümleri ve bu verilerin İPP ile olan ilişkisi istatistiksel olarak karşılaştırıldı. BULGULAR: Hastaların %30’unda (n: 27) evre 1, %40’ında (n: 36) evre 2 ve %30’unda (n: 27) evre 3 İPP mevcuttu. Hastaların yaş ortalaması 64.8 ± 7.54 (42-77) yıl ve ortalama total PSA değeri 7.88 ± 4.75 (2-26) ng/mL olarak bulundu. Gruplar arasındaki prostat kanseri görülme oranları istatistiksel olarak anlamlıydı (p

The Predictive Value of İntravesical Prostatic Protrusion on Prostate Histopathology

INTRODUCTION: One of the important markers of bladder outlet obstruction in benign prostatic hyperplasia is intravesical prostatic protrusion (IPP). In this study, we aimed to show the correlation between IPP and benign pathologies in patients who underwent transrectal ultrasound (TRUSG) biopsy due to high prostate specific antigen (PSA). METHODS: Ninety patients who underwent ransrectal ultrasound guided (TRUSG) biopsy between January 2018 and January 2020 were included in the study. Age, PSA, IPP measure and pathology results of patients were recorded. The patients were divided into 3 groups according to the degree of protrusion. PSA values, pathology results, prostate volumes were compared statistically. RESULTS: 30% (n: 27) Of patients had stage 1, 40% (n: 36) had stage 2 and 30% (n: 27) had stage 3 IPP. The mean age of the patients was 64.8 ± 7.54 (42-77) years and the mean total PSA value was 7.88 ± 4.75 (2-26) ng / mL. The incidence of prostate cancer among the groups was statistically significant (p

PDF

___

1. Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int. 2003, pp. 91: 371–374.
2. Mariappan P, Brown DJ, McNeill AS. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study. J Urol. 2007, s. 178: 573–577.
3. Rieken M, Presicce F, Autorino R, DE Nunzio C. Clinical significance of intravesical prostatic protrusion in the management of benign prostatic enlargement: a systematic review and critical analysis of current evidence. Minerva Urol Nefrol. . 2017, s. 69(6):548-555.
4. Lim KB, Ho H, Foo KT. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int. J. Urol. 2006, s. 13: 1509–1513.
5. Hirayama K, Masui K, Hamada a, Shichiri Y, Masuzawa n, Hamada S. evaluation of intravesical Prostatic Protrusion as a Predictor of Dutasterideresistant lower Urinary Tract Symptoms/Benign Prostatic enlargement With a High likelihood of Surgical intervention. Urology. 2015, s. 86:565- 569.
6. Yoshida T, Kinoshita H, Yoshida K, Mishima T, Taniguchi H, Yanishi M. intravesical Prostatic Protrusion as a Predicting factor for the adverse clinical outcome in Patients With Symptomatic Benign Prostatic enlargement Treated With Dutasteride. Urology. 2016, s. 91:154-157.
7. Garg G, Sankhwar SN, Goel A, Pandey S, Sharma D, Parihar A. Evaluation of resistive index of the prostate and bladder sonomorphologic parameters as replacements for urodynamics to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Low Urin Tract Symptoms. 2019;11(3):163-168.
8. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999, s. 53(3):581– 589.
9. Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology. 2006, s. 68(2):352– 356.
10. Kadihasanoglu M, Aydin M,Taskiran M, Kendirci M. The Effect of Intravesical Prostatic Protrusion in Patients with Benign Prostatic Hyperplasia: Controlled, Clinical Study. Urol Int. 2018, s. 103(2):180-186.
11. Xu D, Yu Y, Zhu Y, Huang T, Chen Y, Qi J. A new model consists of intravesical prostatic protrusion, prostate volume and serum prostaticspecific antigen in the evaluation of prostate cancer. Pathol Oncol Res. 2014, s. 20(2):439-443.